^
Association details:
| Biomarker: | NT5E underexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma
Published date:
11/16/2022
Excerpt:
In addition, we used a cohort of metastatic urothelial carcinomas (IMvigor210 cohort) that had actually received anti-PD-L1 immunotherapy to validate this result, and CD73 expression was indeed lower in the group that responded to immunotherapy (P = 0.0025).
DOI:
10.3389/fimmu.2022.969034
